An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report says prescriptions for two popular weight-loss drugs — semaglutide (the active ingredient in medicines like Ozempic and Wegovy) and tirzepatide (sold as Zepbound and Mounjaro) — are expected to keep rising through 2025. The story is basically about how more people are getting these drugs and how demand looks set to grow over the next year or so. It notes a clear upward trend in prescribing, without claiming any sudden breakthroughs in the medicines themselves. Semaglutide and tirzepatide are synthetic versions of signals your body uses to control appetite and blood sugar. Semaglutide copies a gut hormone that tells your brain you’re full and slows how fast your stomach empties. Tirzepatide acts on two related hormones, so it both reduces appetite and helps control blood sugar. Both are given by injection and were developed originally to treat diabetes; doctors and regulators later approved higher doses for chronic weight management. The coverage is about prescription trends, not a new clinical trial. That means the story is tracking how many prescriptions are being written and projected growth through 2025, rather than claiming new evidence that the drugs work differently. Other studies have already shown both drugs can cause substantial weight loss in many people, but this business-focused piece is reporting on market and prescribing patterns — more doctors are prescribing them, and more patients appear to be using them. It doesn’t provide detailed data on how effective they are for every individual or new safety findings. Why this matters is mostly practical. If more people use these drugs, it affects access, wait times, and price. People who already benefit from them might worry about shortages or higher costs. Others curious about medical weight loss might find it easier to get a prescription as doctors become more comfortable prescribing these medicines. On the healthcare side, rising use can change how clinics operate and how insurers decide what they’ll cover. There are important caveats. These medicines can cause side effects like nausea, diarrhea, and constipation, and they aren’t right for everyone. Long-term effects are still being studied, and supply or cost pressures could limit access. Also, tracking prescription growth doesn’t mean the drugs are a miracle cure — results vary by person, and lifestyle and medical supervision remain important. Finally, this report appears to be about prescribing trends, not new scientific proof, so it shouldn’t be read as new clinical evidence. Bottom line: prescriptions for semaglutide and tirzepatide are rising and expected to keep growing through 2025, which could improve access for some but also raises questions about cost, supply, and long-term use.
Source: BusinessWorld Online